Roberto De Lisa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roberto De Lisa has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Céline Chu
Department of Europe and Innovation, Agence nationale de sécurité du médicament et des produits de santé (ANSM)
1 shared publication- Dimitrios Athanasiou
World Duchenne Organization, Veenendaal, The Netherlands
1 shared publication Elena H Martinez-Lapiscina
European Medicines Agency (EMA)
1 shared publication- Fernando de Andres Trelles
Universidad Complutense
1 shared publication - Sabine Scherer
Paediatric and Orphan Medicinal Products Unit, Federal Institute for Drugs and Medical Devices (BfArM)
1 shared publication - Sylvie Benchetrit
Department of Europe and Innovation, Agence nationale de sécurité du médicament et des produits de santé (ANSM)
1 shared publication
Latest Publications
- Open Access
- 18 November 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (3) , 405-419
Paediatric medicines development for Duchenne muscular dystrophy: An EU regulatory perspective
Background: Duchenne muscular dystrophy (DMD) is a severe muscle disease with an unmet therapeutic need. Despite ongoing research efforts, only a few medicines have achieved marketing authorisation in the EU to date. We present a regulatory science overview summarising the insights obtained from the evaluation by the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) of paediatric investigation plans (PIPs) for this condition, with the primary objective of providing recommendations for future developments. Methods: We reviewed the PIPs approved by the PDCO and related regulatory procedures analysimg the available information in our own databases completing it with a search in the EU Clinical Trials Register (EudraCT) and Clinical Trials Information System (CTIS) databases to provide context. Results: Between January 2005 and December 2024, 16 PIPs were agreed. By 2024, 1 PIP has been completed, the remaining ones are ongoing. So far, 3 medicines for the treatment of DMD have received a positive opinion by EMA's Committee for Medicinal Products for Human Use (CHMP). Main characteristics and critical factors contributing to successful developments are outlined. Conclusions: This study presents the first in-depth evaluation of PIPs approved within the EU for DMD offering insights into potential strategic approaches for clinical development of investigational medicinal products. It highlights the accumulated experience of regulators and stakeholders, particularly regarding pivotal trials that establish clinical efficacy in key patient subgroups. Furthermore, it underscores the emerging value of innovative methodologies – such as extrapolation of efficacy and integration of real-world evidence – while acknowledging persistent challenges related to data quality.
- 18 November 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (3) , 405-419
Open AccessPaediatric medicines development for Duchenne muscular dystrophy: An EU regulatory perspective
Background: Duchenne muscular dystrophy (DMD) is a severe muscle disease with an unmet therapeutic need. Despite ongoing research efforts, only a few medicines have achieved marketing authorisation in the EU to date. We present a regulatory science overview summarising the insights obtained from the evaluation by the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) of paediatric investigation plans (PIPs) for this condition, with the primary objective of providing recommendations for future developments. Methods: We reviewed the PIPs approved by the PDCO and related regulatory procedures analysimg the available information in our own databases completing it with a search in the EU Clinical Trials Register (EudraCT) and Clinical Trials Information System (CTIS) databases to provide context. Results: Between January 2005 and December 2024, 16 PIPs were agreed. By 2024, 1 PIP has been completed, the remaining ones are ongoing. So far, 3 medicines for the treatment of DMD have received a positive opinion by EMA's Committee for Medicinal Products for Human Use (CHMP). Main characteristics and critical factors contributing to successful developments are outlined. Conclusions: This study presents the first in-depth evaluation of PIPs approved within the EU for DMD offering insights into potential strategic approaches for clinical development of investigational medicinal products. It highlights the accumulated experience of regulators and stakeholders, particularly regarding pivotal trials that establish clinical efficacy in key patient subgroups. Furthermore, it underscores the emerging value of innovative methodologies – such as extrapolation of efficacy and integration of real-world evidence – while acknowledging persistent challenges related to data quality.